MRNA vs. RMD: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at MRNA and RMD, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
| Symbol | MRNA | RMD |
|---|---|---|
| Company Name | Moderna, Inc. | ResMed Inc. |
| Country | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Biotechnology | Health Care Equipment & Supplies |
| Market Capitalization | 9.70 billion USD | 36.01 billion USD |
| Exchange | NasdaqGS | NYSE |
| Listing Date | December 7, 2018 | June 2, 1995 |
| Security Type | Common Stock | Common Stock |
Historical Performance
This chart compares the performance of MRNA and RMD by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | MRNA | RMD |
|---|---|---|
| 5-Day Price Return | 0.04% | -2.26% |
| 13-Week Price Return | -11.60% | -14.19% |
| 26-Week Price Return | -2.82% | -1.29% |
| 52-Week Price Return | -41.22% | 3.83% |
| Month-to-Date Return | -8.80% | -0.98% |
| Year-to-Date Return | -40.43% | 6.90% |
| 10-Day Avg. Volume | 11.56M | 1.39M |
| 3-Month Avg. Volume | 10.45M | 1.07M |
| 3-Month Volatility | 59.86% | 19.44% |
| Beta | 1.20 | 0.87 |
Profitability
Return on Equity (TTM)
MRNA
-31.40%
Biotechnology Industry
- Max
- 96.19%
- Q3
- 12.45%
- Median
- -16.39%
- Q1
- -47.43%
- Min
- -131.19%
MRNA has a negative Return on Equity of -31.40%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.
RMD
25.13%
Health Care Equipment & Supplies Industry
- Max
- 29.82%
- Q3
- 15.54%
- Median
- 9.69%
- Q1
- 5.19%
- Min
- -7.98%
In the upper quartile for the Health Care Equipment & Supplies industry, RMD’s Return on Equity of 25.13% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
Net Profit Margin (TTM)
MRNA
-139.61%
Biotechnology Industry
- Max
- 84.13%
- Q3
- 19.34%
- Median
- -1.39%
- Q1
- -117.64%
- Min
- -296.77%
MRNA has a negative Net Profit Margin of -139.61%, indicating the company is operating at a net loss as its expenses exceeded its revenues.
RMD
27.35%
Health Care Equipment & Supplies Industry
- Max
- 24.65%
- Q3
- 14.10%
- Median
- 10.09%
- Q1
- 5.84%
- Min
- -6.13%
RMD’s Net Profit Margin of 27.35% is exceptionally high, placing it well beyond the typical range for the Health Care Equipment & Supplies industry. This demonstrates outstanding operational efficiency and a strong competitive advantage in converting revenue into profit.
Operating Profit Margin (TTM)
MRNA
-155.15%
Biotechnology Industry
- Max
- 78.85%
- Q3
- 20.86%
- Median
- 0.51%
- Q1
- -128.29%
- Min
- -315.84%
MRNA has a negative Operating Profit Margin of -155.15%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.
RMD
33.18%
Health Care Equipment & Supplies Industry
- Max
- 31.34%
- Q3
- 18.36%
- Median
- 15.07%
- Q1
- 9.62%
- Min
- -0.13%
RMD’s Operating Profit Margin of 33.18% is exceptionally high, placing it well above the typical range for the Health Care Equipment & Supplies industry. This demonstrates outstanding efficiency in managing its core operations, which can be a result of strong pricing power or superior cost control.
Profitability at a Glance
| Symbol | MRNA | RMD |
|---|---|---|
| Return on Equity (TTM) | -31.40% | 25.13% |
| Return on Assets (TTM) | -24.44% | 18.44% |
| Net Profit Margin (TTM) | -139.61% | 27.35% |
| Operating Profit Margin (TTM) | -155.15% | 33.18% |
| Gross Profit Margin (TTM) | 63.49% | 60.05% |
Financial Strength
Current Ratio (MRQ)
MRNA
3.93
Biotechnology Industry
- Max
- 15.83
- Q3
- 7.97
- Median
- 4.06
- Q1
- 2.64
- Min
- 0.72
MRNA’s Current Ratio of 3.93 aligns with the median group of the Biotechnology industry, indicating that its short-term liquidity is in line with its sector peers.
RMD
2.89
Health Care Equipment & Supplies Industry
- Max
- 4.97
- Q3
- 2.92
- Median
- 2.12
- Q1
- 1.54
- Min
- 0.86
RMD’s Current Ratio of 2.89 aligns with the median group of the Health Care Equipment & Supplies industry, indicating that its short-term liquidity is in line with its sector peers.
Debt-to-Equity Ratio (MRQ)
MRNA
0.01
Biotechnology Industry
- Max
- 1.27
- Q3
- 0.62
- Median
- 0.13
- Q1
- 0.00
- Min
- 0.00
MRNA’s Debt-to-Equity Ratio of 0.01 is typical for the Biotechnology industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
RMD
0.11
Health Care Equipment & Supplies Industry
- Max
- 1.62
- Q3
- 0.74
- Median
- 0.47
- Q1
- 0.15
- Min
- 0.00
Falling into the lower quartile for the Health Care Equipment & Supplies industry, RMD’s Debt-to-Equity Ratio of 0.11 points to a conservative financing strategy. This results in lower financial risk but potentially limits strategic investments compared to more leveraged competitors.
Interest Coverage Ratio (TTM)
MRNA
--
Biotechnology Industry
- Max
- 72.37
- Q3
- 1.71
- Median
- -15.18
- Q1
- -65.75
- Min
- -166.46
Interest Coverage Ratio data for MRNA is currently unavailable.
RMD
661.20
Health Care Equipment & Supplies Industry
- Max
- 56.35
- Q3
- 24.86
- Median
- 9.84
- Q1
- 3.86
- Min
- -21.65
With an Interest Coverage Ratio of 661.20, RMD demonstrates a superior capacity to service its debt, placing it well above the typical range for the Health Care Equipment & Supplies industry. This stems from either robust earnings or a conservative debt load.
Financial Strength at a Glance
| Symbol | MRNA | RMD |
|---|---|---|
| Current Ratio (MRQ) | 3.93 | 2.89 |
| Quick Ratio (MRQ) | 3.40 | 1.87 |
| Debt-to-Equity Ratio (MRQ) | 0.01 | 0.11 |
| Interest Coverage Ratio (TTM) | -- | 661.20 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
MRNA
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
MRNA currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
RMD
0.90%
Health Care Equipment & Supplies Industry
- Max
- 4.36%
- Q3
- 1.87%
- Median
- 0.82%
- Q1
- 0.00%
- Min
- 0.00%
RMD’s Dividend Yield of 0.90% is consistent with its peers in the Health Care Equipment & Supplies industry, providing a dividend return that is standard for its sector.
Dividend Payout Ratio (TTM)
MRNA
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
MRNA has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
RMD
22.31%
Health Care Equipment & Supplies Industry
- Max
- 160.00%
- Q3
- 67.77%
- Median
- 28.21%
- Q1
- 0.00%
- Min
- 0.00%
RMD’s Dividend Payout Ratio of 22.31% is within the typical range for the Health Care Equipment & Supplies industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
Dividend at a Glance
| Symbol | MRNA | RMD |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.90% |
| Dividend Payout Ratio (TTM) | 0.00% | 22.31% |
Valuation
Price-to-Earnings Ratio (TTM)
MRNA
--
Biotechnology Industry
- Max
- 115.91
- Q3
- 56.76
- Median
- 21.80
- Q1
- 15.79
- Min
- 4.51
P/E Ratio data for MRNA is currently unavailable.
RMD
24.87
Health Care Equipment & Supplies Industry
- Max
- 67.59
- Q3
- 41.41
- Median
- 33.11
- Q1
- 22.82
- Min
- 8.68
RMD’s P/E Ratio of 24.87 is within the middle range for the Health Care Equipment & Supplies industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
Price-to-Sales Ratio (TTM)
MRNA
4.30
Biotechnology Industry
- Max
- 58.56
- Q3
- 29.31
- Median
- 8.30
- Q1
- 4.89
- Min
- 0.86
In the lower quartile for the Biotechnology industry, MRNA’s P/S Ratio of 4.30 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.
RMD
6.80
Health Care Equipment & Supplies Industry
- Max
- 9.49
- Q3
- 5.41
- Median
- 2.92
- Q1
- 1.97
- Min
- 0.61
RMD’s P/S Ratio of 6.80 is in the upper echelon for the Health Care Equipment & Supplies industry. This means the company is valued richly on its revenue stream compared to its peers, suggesting the stock is priced for a high level of future performance.
Price-to-Book Ratio (MRQ)
MRNA
1.08
Biotechnology Industry
- Max
- 17.92
- Q3
- 10.38
- Median
- 4.78
- Q1
- 2.85
- Min
- 0.78
MRNA’s P/B Ratio of 1.08 is in the lower quartile for the Biotechnology industry. From a value investing perspective, this is favorable, as it suggests the stock is trading at a discount to its net asset value and may offer a greater margin of safety.
RMD
6.53
Health Care Equipment & Supplies Industry
- Max
- 10.77
- Q3
- 6.04
- Median
- 3.32
- Q1
- 2.31
- Min
- 0.83
RMD’s P/B Ratio of 6.53 is in the upper tier for the Health Care Equipment & Supplies industry. This indicates that investors are paying a premium relative to the company’s net assets, a valuation that hinges on its ability to generate superior profits.
Valuation at a Glance
| Symbol | MRNA | RMD |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | -- | 24.87 |
| Price-to-Sales Ratio (TTM) | 4.30 | 6.80 |
| Price-to-Book Ratio (MRQ) | 1.08 | 6.53 |
| Price-to-Free Cash Flow Ratio (TTM) | 31.69 | 20.36 |